References
- Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70:1–20
- Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res 2009;26:1025–1058
- Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001;47:165–196
- Barichello JM, Morishita M, Takayama K, Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm 1999;4:471–476
- Bilati U, Allemann E, Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci 2005;24:67–75
- Puri S, Kallinteri P, Higgins S, et al. Drug incorporation and release of water soluble drugs from novel functionalized poly(glycerol adipate) nanoparticles. J Control Release 2008;125:59–67
- Peltonen L, Aitta J, Hyvonen S, et al. Improved entrapment efficiency of hydrophilic drug substance during nanoprecipitation of poly(l)lactide nanoparticles. AAPS PharmSciTech 2004;5:115–120
- Govender T, Stolnik S, Garnett MC, et al. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release 1999;57:171–185
- Dash TK, Konkimalla VB. Poly-small je, Ukrainian-caprolactone based formulations for drug delivery and tissue engineering: a review. J Control Release 2012;158:15–33
- Vuddanda PR, Chakraborty S, Singh S. Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert Opin Investig Drugs 2010;19:1297–1307
- Affuso F, Mercurio V, Fazio V, Fazio S. Cardiovascular and metabolic effects of Berberine. World J Cardiol 2010;2:71–77
- Tang J, Feng YB, Tsao S, et al. Berberine and Coptidis Rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol 2009;126:5–17
- Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 2008;22:999–1012
- Kulkarni SK, Dhir A. Current investigational drugs for major depression. Expert Opin Investig Drugs 2009;18:767–788
- Nassar T, Rom A, Nyska A, Benita S. Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug. J Control Release 2009;133:77–84
- Shapira A, Livney YD, Broxterman HJ, Assaraf YG. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Update 2011;14:150–163
- Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 2004;99:259–269
- Chakraborty P, Dey S, Parcha V, et al. Design expert supported mathematical optimization and predictability study of buccoadhesive pharmaceutical wafers of Loratadine. BioMed Res Int 2013;2013:197398 (1–2)
- Singh S, Muthu MS. Preparation and characterization of nanoparticles containing an atypical antipsychotic agent. Nanomedicine (Lond) 2007;2:233–240
- Bisht S, Feldmann G, Soni S, et al. Polymeric nanoparticle-encapsulated curcumin (“nanocurcumin”): a novel strategy for human cancer therapy. J Nanobiotechnol 2007;5:3(1–18)
- Battu SK, Repka MA, Maddineni S, et al. Physicochemical characterization of berberine chloride: a perspective in the development of a solution dosage form for oral delivery. AAPS PharmSciTech 2010;11:1466–1475
- Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm 2005;290:137–144
- Li N, Xu L. Thermal analysis of β-cyclodextrin/Berberine chloride inclusion compounds. Thermochim Acta 2010;499:166–170
- Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123–133
- Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 1985;60:110–111